Company news

Editas Medicine, Inc. news in 2022

Editas Medicine, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

December 5, 2022

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

November 30, 2022

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

November 16, 2022

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

November 1, 2022

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

October 25, 2022

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

October 12, 2022

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

August 2, 2022

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

July 26, 2022

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

July 25, 2022

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

July 19, 2022

Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

July 17, 2022

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

June 6, 2022

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

June 5, 2022

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

May 17, 2022

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

May 11, 2022

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

May 3, 2022

Editas Medicine Announces First Quarter 2022 Results and Business Updates

May 3, 2022

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

May 1, 2022

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

April 26, 2022

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

April 25, 2022

Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer

April 13, 2022

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

April 10, 2022

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

April 7, 2022

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

February 27, 2022

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

February 23, 2022

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

February 15, 2022

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

January 9, 2022

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Calls in 2022

Decks in 2022